Hoth Therapeutics Inc
NASDAQ:HOTH

Watchlist Manager
Hoth Therapeutics Inc Logo
Hoth Therapeutics Inc
NASDAQ:HOTH
Watchlist
Price: 1.07 USD 2.88% Market Closed
Market Cap: 16.6m USD

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Hoth Therapeutics Inc
NASDAQ:HOTH
16.2m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
984.9B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
525.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
207.6B GBP
Loading...
CH
Novartis AG
SIX:NOVN
218.5B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.2B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.1B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Hoth Therapeutics Inc
Glance View

Market Cap
16.6m USD
Industry
Pharmaceuticals

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.

HOTH Intrinsic Value
0.51 USD
Overvaluation 52%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top